Skip to main content
User Image

حمد بن مسفر القحطاني

Associate Professor

عضو هيئة تدريس

كلية الصيدلة
2 أ 144
publication
Journal Article
2019

Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation

Darwish, Mohammed M Alanazi, Hamad M Alkahtani, Abdulrahman A Almehizia, Mohamed W Attwa, Ahmed H Bakheit, Hany W . 2019

Foretinib (GSK1363089, FTB) is a multikinase inhibitor that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor-2 and mesenchymal–epithelial transition factor, with the potential for solid tumor treatment. Lapatinib (LPB) is a significant promising drug molecule that was approved by the USFDA and was utilized to develop a nontoxic and very efficient targeted therapy against breast cancer. There is an ongoing clinical trial for using of FTB and LPB combination for HER-2 positive metastatic breast cancer treatment. In the current study, liquid chromatography tandem mass spectrometry methodology was validated for simultaneous estimation of FTB and LPB with application to drug metabolic stability investigation. Chromatographic separation of FTB, LPB and masitinib (internal standard) was attained using an isocratic mobile phase running on a reversed-phase C18 column. The linear dynamic range was 5–500 ng mL−1 with r2 ≥ 0.9999 in the rat liver microsomes (RLMs) matrix. The FTB and LPB metabolic stabilities in the RLMs matrix were estimated by computing two parameters, intrinsic clearance (CLint: 6.33 and 5.63 mL min−1 kg−1) and a low in vitro half-life (t1/2: 23.9 and 26.9 min), which revealed the FTB and LPB high clearance by the liver from the blood. This probably revealed the low in vivo bioavailability that verified the low oral bioavailability previously reported and also indicated that FTB and LPB will not bioaccumulate after multiple doses. FTB metabolic rate is slightly decreased in combination with LPB, while LPB metabolic rate is greatly increased in combination with FTB. So dose recalculation must be evaluated when FTB and LPB are used in combination.

Volume Number
9
Issue Number
34
Magazine \ Newspaper
RSC Advances
Pages
19325-19332
more of publication
publications

Heterocyclic chemistry is a broad branch of organic chemistry that contributes to almost one-third of all recent publications in the field, and it is becoming a more important subject for research…

by Siddique Akber Ansari , Hamad M. Alkahtani
2023
Published in:
Elsevier
publications

A method of making a pyrazole compound includes mixing a diazonium salt with a reactant in the presence of a solvent, thereby coupling a diazo group of the diazonium salt to an α-carbon atom of…

by Samar A. Abubshait, Haya A. Abubshait, Sara Nabil Shaban, Asma Mohmmad Elsharif, Hamad M. Alkahtani, Fadilah Sfouq Aleanizy, M. Nasiruzzaman SHAIKH
2024
publications

Foretinib (GSK1363089, FTB) is a multikinase inhibitor that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor-2 and mesenchymal–epithelial…

by Mohammed M Alanazi, Hamad M Alkahtani, Abdulrahman A Almehizia, Mohamed W Attwa, Ahmed H Bakheit, Hany W Darwish
2019